Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients - Scorecard - MDSpire
Advertisement
Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients
Clinical Scorecard: Prognostic Significance of RAS Pathway Mutations in Acute Myeloid Leukemia: A Study of 2,500 Patients Based on Gene and Subtype Variations
At a Glance
Category
Detail
Condition
Key Mechanisms
Constitutive activation of RAS/MAPK signaling pathway due to mutations in RAS family members and their regulators.
Target Population
Care Setting
Key Highlights
Approximately 25-30% of AML patients have RAS pathway mutations.
NRAS mutations are associated with favorable outcomes in AML.
PTPN11 mutations correlate with inferior event-free survival (EFS).
KRAS and NF1 mutations are enriched in adverse-risk AML.
The study analyzed a cohort of 2500 AML patients using updated risk classification.
Guideline-Based Recommendations
Diagnosis
Utilize targeted next-generation sequencing panels for mutation analysis.
Management
Consider RAS pathway mutation status when stratifying risk and planning treatment.
Monitoring & Follow-up
Monitor overall survival (OS) and event-free survival (EFS) based on mutation status.
Risks
Patients with PTPN11 mutations may have worse outcomes.
Patient & Prescribing Data
2500 AML patients, median age 41 years.
Patients with NRAS mutations showed significantly superior OS and EFS.
Clinical Best Practices
Adhere to the European LeukemiaNet AML risk classification guidelines (ELN 2022).
Evaluate the presence of RAS pathway mutations for prognostic assessment.
